» Articles » PMID: 38664296

The Prevalence of Mild Cognitive Impairment in Breast Cancer Patients Receiving Chemotherapy According to the Criteria of the National Institute on Aging-Alzheimer's Association (NIA-AA)

Overview
Journal J Cancer Surviv
Specialty Oncology
Date 2024 Apr 25
PMID 38664296
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Breast cancer patients receiving chemotherapy can develop cognitive impairment. There is no gold standard for defining cognitive impairment. We applied the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for mild cognitive impairment (MCI) to determine its prevalence in breast cancer patients receiving adjuvant chemotherapy and examine differences between patients with and without MCI.

Methods: We used pre-existing cognitive data on 5 neuropsychological test outcomes (verbal memory, processing speed, executive functioning, and verbal fluency) gathered from 240 breast cancer patients who received adjuvant conventional (n = 154) or high-dose chemotherapy (n = 86). Assessments occurred 6 or 12 months post-chemotherapy and results were compared with data from 66 women without cancer. MCI was defined by the following: (i) presence of concern regarding a change in cognition, (ii) impairment in one or more cognitive tests (1.5 standard deviation below a normative mean), (iii) preservation of independence in functional abilities, and (iv) the absence of dementia.

Results: Twenty percent (n = 49) of breast cancer patients who received chemotherapy (conventional therapy n = 29 (12%), high-dose therapy = 20 (8.3%)) met the criteria for MCI, compared with 7.6% (n = 5) of controls. Prevalence was significantly different between patients and controls (P = 0.020, and corrected for IQ P < 0.001). Patients with MCI had significant lower education levels (P < 0.002) and premorbid IQ (P = 0.001) compared with patients without MCI.

Conclusions: Twenty percent of breast cancer patients treated with chemotherapy met NIA-AA criteria for MCI, compared with 7.6% of the controls.

Implications For Cancer Survivors: These criteria, which include formal test performance as well as a person's symptoms and functional status, can be useful in clinical practice and scientific research.

Citing Articles

Bidirectional association between breast cancer and dementia: a systematic review and meta-analysis of observational studies.

Bao F, Yu L, Zhang X, Mu Q PeerJ. 2025; 13:e18888.

PMID: 39902325 PMC: 11789662. DOI: 10.7717/peerj.18888.


Development and validation of a risk prediction model for cognitive impairment in breast cancer patients.

Zhang X, Lu J, Ding Z, Qiao Y, Li X, Zhong G BMC Psychiatry. 2024; 24(1):809.

PMID: 39548422 PMC: 11566113. DOI: 10.1186/s12888-024-06278-x.

References
1.
Kaplan H, Malmgren J, Atwood M, Calip G . Effect of treatment and mammography detection on breast cancer survival over time: 1990-2007. Cancer. 2015; 121(15):2553-61. PMC: 5705063. DOI: 10.1002/cncr.29371. View

2.
Dijkshoorn A, van Stralen H, Sloots M, Schagen S, Visser-Meily J, Schepers V . Prevalence of cognitive impairment and change in patients with breast cancer: A systematic review of longitudinal studies. Psychooncology. 2021; 30(5):635-648. PMC: 8248098. DOI: 10.1002/pon.5623. View

3.
Fleming B, Edison P, Kenny L . Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management. BMJ. 2023; 380:e071726. DOI: 10.1136/bmj-2022-071726. View

4.
Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L . Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019; 30(12):1925-1940. PMC: 8109411. DOI: 10.1093/annonc/mdz410. View

5.
Wefel J, Saleeba A, Buzdar A, Meyers C . Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010; 116(14):3348-56. DOI: 10.1002/cncr.25098. View